During the European Association for Cancer Research (EACR) Annual Congress 2024 for Innovative Cancer Science in #Rotterdam, we had the opportunity to present our internal #research: “Targeting HER3 in Cancer Therapy: Pioneering Approaches through DNA Vaccination and Monoclonal Antibody Development.”
This study introduced a dual approach targeting #HER3 with a therapeutic #vaccine and a novel monoclonal #antibody strategy, exploring potential extensions to vectorized antibody expression and advanced therapeutics.
We developed a genetic #cancer vaccine using #DNA vectors for HER3, delivered via DNA electro-gene-transfer (DNA-EGT) into BALB/NeuT mice, inducing a specific immune response and long-term immunologic memory to prevent relapse.
Concurrently, we generated hybridomas against human ErbB3 through DNA-EGT, selecting monoclonal antibodies that effectively inhibit ErbB3 signaling.
Results showed that DNA-EGT vaccination robustly prevented cancer onset and slowed tumor progression. Additionally, the anti-ErbB3 monoclonal antibodies demonstrated effective in vitro and in vivo antitumor properties.
If you want to know more about our research, contact us here on LinkedIn!
